Compounds > dilazep
Page last updated: 2024-10-26

dilazep and Hemoglobinopathies

dilazep has been researched along with Hemoglobinopathies in 2 studies

Dilazep: Coronary vasodilator with some antiarrhythmic activity.
dilazep : A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties.

Hemoglobinopathies: A group of inherited disorders characterized by structural alterations within the hemoglobin molecule.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Opartkiattikul, N2
Sukpanichnant, S1
Funahara, Y2
Sumiyoshi, A1
Wanachiwanawin, W1
Tatsumi, N1
Fucharoen, S2
Talalak, P1

Trials

1 trial available for dilazep and Hemoglobinopathies

ArticleYear
Cross over placebo control trial of dilazep in beta-thalassemia/hemoglobin E patients.
    The Southeast Asian journal of tropical medicine and public health, 1999, Volume: 30, Issue:2

    Topics: Adolescent; Adult; beta-Thalassemia; Blood Transfusion; Cross-Over Studies; Dilazep; Female; Hemoglo

1999

Other Studies

1 other study available for dilazep and Hemoglobinopathies

ArticleYear
Increase in spontaneous platelet aggregation in beta-thalassemia/hemoglobin E disease: a consequence of splenectomy.
    The Southeast Asian journal of tropical medicine and public health, 1992, Volume: 23 Suppl 2

    Topics: Adult; Ambulatory Care Facilities; beta-Thalassemia; Blood Platelet Disorders; Centrifugation; Dilaz

1992